KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Intangibles (2019 - 2025)

Pacira BioSciences has reported Intangibles over the past 13 years, most recently at $368.1 million for Q4 2025.

  • Quarterly results put Intangibles at $368.1 million for Q4 2025, down 13.59% from a year ago — trailing twelve months through Dec 2025 was $368.1 million (down 13.59% YoY), and the annual figure for FY2025 was $368.1 million, down 13.59%.
  • Intangibles for Q4 2025 was $368.1 million at Pacira BioSciences, down from $382.4 million in the prior quarter.
  • Over the last five years, Intangibles for PCRX hit a ceiling of $624.0 million in Q4 2021 and a floor of $90.6 million in Q3 2021.
  • Median Intangibles over the past 5 years was $461.8 million (2024), compared with a mean of $432.3 million.
  • Biggest five-year swings in Intangibles: surged 546.46% in 2021 and later fell 14.36% in 2023.
  • Pacira BioSciences' Intangibles stood at $624.0 million in 2021, then fell by 13.37% to $540.5 million in 2022, then dropped by 10.6% to $483.3 million in 2023, then fell by 11.85% to $426.0 million in 2024, then decreased by 13.59% to $368.1 million in 2025.
  • The last three reported values for Intangibles were $368.1 million (Q4 2025), $382.4 million (Q3 2025), and $422.6 million (Q2 2025) per Business Quant data.